rediff.com

News APP

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  gplay

Sign in  |  Create a Rediffmail account

Pfizer India

Subscribe via RSS
Rediff.com  »  News  »   Pfizer India

  News for Pfizer India

  • News
  • Business

In talks with India over 'expedited approval' of Covid vaccine: Pfizer

 Pfizer is in discussions with the Indian government for an expedited approval pathway to make Pfizer-BioNTech vaccine available in the country, its chief Albert Bourla said on Monday, while stating......

Pfizer seeks approval in India for Covid vaccine

 Pfizer India has become the first pharmaceutical firm to seek from the Drugs Controller General of India an emergency use authorisation for its COVID-19 vaccine in the country, after its parent......

Moderna's single-dose COVID-19 vaccine in India likely next year; Pfizer ready with 5 cr doses for 2021

 Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots......

AstraZeneca's COVID-19 Vaccine: The TTS Factor

 'It is admitted that the AZ vaccine can, in very rare cases, cause TTS.' IMAGE: A vial labelled 'AstraZeneca COVID-19 Vaccine'. Photograph: Illustration/Dado Ruvic/Reuters   The controversial......

India may not buy Pfizer, Moderna vaccines

 India is unlikely to buy Pfizer and Moderna COVID-19 vaccines for now as the domestic manufacturing of anti-coronavirus jabs has picked up pace, sources said with the total doses administered in......

India undermining intellectual property: Pfizer

 Months after its patent for a cancer medication was revoked by India, American firm Pfizer has told US lawmakers that New Delhi is undermining intellectual property by misuse of its......

Why 1,700 employees of Pfizer's India arm may lose their jobs

 A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations. US pharmaceutical major Pfizer has......

Q3 result preview: US, India to aid revenue growth for Pharma Inc

 The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for......

Domestic pharma market grew by 6.8% in 2023

 The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. Photograph: Amit......

Largecap, midcap cutoff surges over 26% in latest Amfi classification

 The rally in the equity markets in the second half of 2023 has led to a sharp surge in the cutoff for stocks to qualify as largecaps and midcaps. Illustration: Dominic Xavier/Rediff.com On the......

Related Tags

  1. gujarat
  2. bjp
  3. india
  4. lok sabha
  5. supreme court
  6. upa
  7. bharatiya janata party
  8. congress
  9. new delhi
  10. united progressive alliance
  11. ahmedabad
  12. sonia gandhi
  13. nda
  14. rahul gandhi
  15. rajnath singh
  16. nitin gadkari
  17. delhi
  18. manmohan singh
  19. bihar
  20. national democratic alliance
  21. jd-u
  22. nitish kumar
  23. rashtriya swayamsevak sangh
  24. uttar pradesh
  25. photo
  26. advani
  27. central bureau of investigation
  28. rss
  29. janata dal-united
  30. ips

Top Coverage News

World Test Championship 2023

 India held the top position in the ICC Men's Test Team Rankings while Australia secured the...

Manipur's Tragedy

 Here are news, updates and coverage from violence hit Manipur.

IPL 2023

 Complete coverage of IPL 2023

Sri Lanka's Tour of India 2023

 Complete Coverage of Indian cricket team's encounter with Sri Lanka during 3rd Jan - 15th Jan 2023.

GUJARAT, HIMACHAL GO TO POLLS

 The Bharatiya Janata Party was on Thursday poised for a landslide victory in Gujarat to retain...
Broswe by: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
rediff on the net© 2025 Rediff.com - Investors - Advertise - Disclaimer - Privacy - Feedback - About us | Terms of use - Grievances